ADA/EASD update 2026 consensus on adult type 1 diabetes care
This report is a joint ADA/EASD update to the 2021 consensus on managing type 1 diabetes in adults, with revised guidance across all sections reflecting new evidence, clinical advances, and novel therapies. The update emphasizes integration of new technologies, interventions to delay onset of stage 3 type 1 diabetes, and expands scope to include screening for long-term complications and management of obesity and cardiovascular risk factors, while retaining psychosocial care and diabetes self-management education and support as key elements.
Most relevant for: Adults with type 1 diabetes, including those at earlier stages of disease progression and those with obesity or cardiovascular risk factors.
Read the original at Diabetes CareSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More endocrinology updates
- 2025 ATA thyroglobulin cutoff may miss recurrences in higher-risk DTCOct 13, 2026
- ADA-EASD 2026 consensus favors earlier SGLT2/GLP-1 use in type 2 diabetesOct 2, 2026
- Lean MASLD shows milder liver histology but similar clinical outcomesSep 30, 2026
- Oral GLP-1 agonist orforglipron shows cardiovascular non-inferiority to insulin glargineSep 30, 2026
- Retatrutide Trial Shows Weight Loss and Comorbidity Benefits in ObesitySep 29, 2026